Cargando…

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan

OBJECTIVE: Hyponatremia is frequently observed in patients with decompensated liver cirrhosis and it is also related to a poor prognosis. The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic patients with ascites and increases the serum sodium (Na) level. In this study, we inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kogiso, Tomomi, Kobayashi, Mutsuki, Yamamoto, Kuniko, Ikarashi, Yuichi, Kodama, Kazuhisa, Taniai, Makiko, Torii, Nobuyuki, Hashimoto, Etsuko, Tokushige, Katsutoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725852/ https://www.ncbi.nlm.nih.gov/pubmed/28943585 http://dx.doi.org/10.2169/internalmedicine.9033-17

Ejemplares similares

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Successful Treatment of Ascites using a Denver(Ⓡ) Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome
por: Kogiso, Tomomi, et al.
Publicado: (2016)

The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus
por: Ikarashi, Yuichi, et al.
Publicado: (2017)

Differences in the genetic backgrounds of patients with alcoholic liver disease and non‐alcoholic fatty liver disease
por: Yamamoto, Kuniko, et al.
Publicado: (2018)

Characteristics of NAFLD Based on Hypopituitarism
por: Kodama, Kazuhisa, et al.
Publicado: (2020)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Atypical Sarcoidosis Diagnosed by Massive Splenomegaly
por: Saito, Satomi, et al.
Publicado: (2019)

Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality
por: Ogasawara, Yuri, et al.
Publicado: (2023)

Analysis of genetic factors associated with fatty liver disease‐related hepatocellular carcinoma
por: Kogiso, Tomomi, et al.
Publicado: (2023)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Bardet-Biedl Syndrome Caused by Skipping of SCLT1 Complicated by Microvesicular Steatohepatitis
por: Horiuchi, Kentaro, et al.
Publicado: (2020)

Long‐term outcome of Wilson's disease complicated by liver disease
por: Arai, Satoko, et al.
Publicado: (2021)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study
por: Kogiso, Tomomi, et al.
Publicado: (2017)

Risk factors for Fontan-associated hepatocellular carcinoma
por: Kogiso, Tomomi, et al.
Publicado: (2022)

The Relationship between the Growth Hormone/Insulin-like Growth Factor System and the Histological Features of Nonalcoholic Fatty Liver Disease
por: Chishima, Sayaka, et al.
Publicado: (2017)

Questionnaire survey on lifestyle of patients with nonalcoholic steatohepatitis
por: Noto, Haruka, et al.
Publicado: (2014)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Long-term Follow-up of a Patient with Portal Hypertension and Hepatic Failure Due to Hepatic Hydatid Disease
por: Takenaka, Yuki, et al.
Publicado: (2021)

Giant Hepatic Hemangioma Causing Prolonged Fever and Indicated for Resection
por: Yoshimizu, Chihiro, et al.
Publicado: (2021)

The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Fontan-associated liver disease and hepatocellular carcinoma in adults
por: Kogiso, Tomomi, et al.
Publicado: (2020)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
por: Shiba, Shunsuke, et al.
Publicado: (2020)

Current Therapy and Liver Transplantation for Portopulmonary Hypertension in Japan
por: Tokushige, Katsutoshi, et al.
Publicado: (2023)

Hormone-replacement Therapy for Hepatopulmonary Syndrome and NASH Associated with Hypopituitarism
por: Torii, Nobuyuki, et al.
Publicado: (2018)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

Risk factors for fatty pancreas and effects of fatty infiltration on pancreatic cancer
por: Otsuka, Nao, et al.
Publicado: (2023)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
por: Tang, Jieting, et al.
Publicado: (2020)

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r4385vrltf2vv83mlpfa4a93vg